Published online before print June 14, 2004, doi: 10.1161/01.CIR.0000134501.57864.66
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:214-219.)
© 2004 American Heart Association, Inc.
Original Articles |
Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus
From the Department of Geriatrics and Metabolic Diseases (K.E.,D.G., F.N., R.M.) and the Cardiovascular Research Center (K.E., D.G., R.M.), Second University of Naples, Naples, Italy.
Correspondence to Prof Dario Giugliano, Department of Geriatrics and Metabolic Diseases, Policlinico Universitario, Piazza L. Miraglia, 80138 Naples, Italy. E-mail dario.giugliano{at}unina2.it
Received November 18, 2003; de novo received January 2, 2004; revision received March 16, 2004; accepted March 22, 2004.
Background— Postprandial hyperglycemia may be a risk factor for cardiovascular disease. We compared the effects of two insulin secretagogues, repaglinide and glyburide, known to have different efficacy on postprandial hyperglycemia, on carotid intima-media thickness (CIMT) and markers of systemic vascular inflammation in type 2 diabetic patients.
Methods and Results— We performed a randomized, single-blind trial on 175 drug-naive patients with type 2 diabetes mellitus (93 men and 82 women), 35 to 70 years of age, selected from a population of 401 patients who participated in an epidemiological analysis assessing the relation of postprandial hyperglycemia to surrogate measures of atherosclerosis. Eighty-eight patients were randomly assigned to receive repaglinide and 87 patients to glyburide, with a titration period of 6 to 8 weeks for optimization of drug dosage and a subsequent 12-month treatment period. The effects of repaglinide (1.5 to 12 mg/d) and glyburide (5 to 20 mg/d) on CIMT were compared by using blinded, serial assessments of the far wall. After 12 months, postprandial glucose peak was 148±28 mg/dL in the repaglinide group and 180±32 mg/dL in the glyburide group (P<0.01). HbA1c showed a similar decrease in both groups (–0.9%). CIMT regression, defined as a decrease of >0.020 mm, was observed in 52% of diabetics receiving repaglinide and in 18% of those receiving glyburide (P<0.01). Interleukin-6 (P=0.04) and C-reactive protein (P=0.02) decreased more in the repaglinide group than in the glyburide group. The reduction in CIMT was associated with changes in postprandial but not fasting hyperglycemia.
Conclusions— Reduction of postprandial hyperglycemia in type 2 diabetic patients is associated with CIMT regression.
Key Words: diabetes mellitus • atherosclerosis • interleukins • carotid arteries
This article has been cited by other articles:
 |
|
 |
|
  S. S Lund, L. Tarnow, C. D A Stehouwer, C. G Schalkwijk, T. Teerlink, J. Gram, K. Winther, M. Frandsen, U. M Smidt, O. Pedersen, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes Eur. J. Endocrinol., May 1, 2008; 158(5): 631 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Esposito, M. Ciotola, D. Carleo, B. Schisano, L. Sardelli, D. Di Tommaso, L. Misso, F. Saccomanno, A. Ceriello, and D. Giugliano Post-Meal Glucose Peaks at Home Associate with Carotid Intima-Media Thickness in Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1345 - 1350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S Lund, L. Tarnow, M. Frandsen, U. M Smidt, O. Pedersen, H.-H. Parving, and A. A Vaag Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes Eur. J. Endocrinol., January 1, 2008; 158(1): 35 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Wolever, A. L Gibbs, C. Mehling, J.-L. Chiasson, P. W Connelly, R. G Josse, L. A Leiter, P. Maheux, R. Rabasa-Lhoret, N W. Rodger, et al. The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein Am. J. Clinical Nutrition, January 1, 2008; 87(1): 114 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Giugliano, A. Ceriello, and K. Esposito Glucose metabolism and hyperglycemia Am. J. Clinical Nutrition, January 1, 2008; 87(1): 217S - 222S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Nielson and R. M. Fleming Blood Glucose and Cerebrovascular Disease in Nondiabetic Patients Angiology, November 1, 2007; 58(5): 625 - 629. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Mita, H. Watada, T. Shimizu, Y. Tamura, F. Sato, T. Watanabe, J. B. Choi, T. Hirose, Y. Tanaka, and R. Kawamori Nateglinide Reduces Carotid Intima-Media Thickening in Type 2 Diabetic Patients Under Good Glycemic Control Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2456 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Davidson Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Jellinger, Lebovitz, and Davidson Diabetes Care, April 1, 2007; 30(4): e18 - e20. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Giugliano and K. Esposito Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness JAMA, March 28, 2007; 297(12): 1315 - 1316. [Full Text] [PDF]
|
|
|
|
|
|
C. G. Parkin and J. A. Davidson Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al. Diabetes Care, January 1, 2007; 30(1): 192 - 193. [Full Text] [PDF]
|
|
|
|
|
|
B. P. Kovatchev, E. Otto, D. Cox, L. Gonder-Frederick, and W. Clarke Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care, November 1, 2006; 29(11): 2433 - 2438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yokoyama, N. Katakami, and Y. Yamasaki Recent Advances of Intervention to Inhibit Progression of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes Mellitus Stroke, September 1, 2006; 37(9): 2420 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Abbatecola, M. R. Rizzo, M. Barbieri, R. Grella, A. Arciello, M. T. Laieta, R. Acampora, N. Passariello, F. Cacciapuoti, and G. Paolisso Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology, July 25, 2006; 67(2): 235 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Gerich Clinicians can help their patients control postprandial hyperglycemia as a means of reducing cardiovascular risk. The Diabetes Educator, July 1, 2006; 32(4): 513 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Kilpatrick, A. S. Rigby, and S. L. Atkin The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes Diabetes Care, July 1, 2006; 29(7): 1486 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cavalot, A. Petrelli, M. Traversa, K. Bonomo, E. Fiora, M. Conti, G. Anfossi, G. Costa, and M. Trovati Postprandial Blood Glucose Is a Stronger Predictor of Cardiovascular Events Than Fasting Blood Glucose in Type 2 Diabetes Mellitus, Particularly in Women: Lessons from the San Luigi Gonzaga Diabetes Study J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 813 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sander, C. Schulze-Horn, H. Bickel, H. Gnahn, E. Bartels, and B. Conrad Combined Effects of Hemoglobin A1c and C-Reactive Protein on the Progression of Subclinical Carotid Atherosclerosis: The INVADE Study Stroke, February 1, 2006; 37(2): 351 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Esposito and D. Giugliano Diet and inflammation: a link to metabolic and cardiovascular diseases Eur. Heart J., January 1, 2006; 27(1): 15 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Thule, A. G. Campbell, D. J. Kleinhenz, D. E. Olson, J. J. Boutwell, R. L. Sutliff, and C. M. Hart Hepatic insulin gene therapy prevents deterioration of vascular function and improves adipocytokine profile in STZ-diabetic rats Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E114 - E122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shiraiwa, H. Kaneto, T. Miyatsuka, K. Kato, K. Yamamoto, A. Kawashima, T. Kanda, M. Suzuki, E. Imano, M. Matsuhisa, et al. Postprandial Hyperglycemia Is a Better Predictor of the Progression of Diabetic Retinopathy Than HbA1c in Japanese Type 2 Diabetic Patients Diabetes Care, November 1, 2005; 28(11): 2806 - 2807. [Full Text] [PDF]
|
|
|
|
|
|
V. Valentine Continuous Glucose Monitoring Has Left the Station: Are You Onboard? The Diabetes Educator, September 1, 2005; 31(5): 649 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. B. Hirsch, R. M. Bergenstal, C. G. Parkin, E. Wright Jr., and J. B. Buse A Real-World Approach to Insulin Therapy in Primary Care Practice Clin. Diabetes, April 1, 2005; 23(2): 78 - 86. [Full Text] [PDF]
|
|
|
|
|
|
A. Ceriello, L. Piconi, L. Quagliaro, Y. Wang, C. A. Schnabel, J. A. Ruggles, M. A. Gloster, D. G. Maggs, and C. Weyer Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes Diabetes Care, March 1, 2005; 28(3): 632 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ceriello, D. Johns, M. Widel, D. J. Eckland, K. J. Gilmore, and M. H. Tan Comparison of Effect of Pioglitazone With Metformin or Sulfonylurea (Monotherapy and Combination Therapy) on Postload Glycemia and Composite Insulin Sensitivity Index During an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes Diabetes Care, February 1, 2005; 28(2): 266 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ceriello, M. Hanefeld, L. Leiter, L. Monnier, A. Moses, D. Owens, N. Tajima, J. Tuomilehto, and for the International Prandial Glucose Regulation Postprandial Glucose Regulation and Diabetic Complications Arch Intern Med, October 25, 2004; 164(19): 2090 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. B. Hirsch Were We Wrong About Insulin and Acute Myocardial Infarction? DOC News, October 1, 2004; 1(2): 4 - 5. [Full Text]
|
|